Cargando…
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
Enzyme replacement therapy (ERT) has been widely used for the treatment of Fabry disease, a rare X-linked recessive disorder due to absent or reduced activity of lysosomal enzyme α-galactosidase A. It is still unclear why some patients under ERT show disease progression typically with renal, cardiov...
Autores principales: | Scionti, Francesca, Di Martino, Maria Teresa, Sestito, Simona, Nicoletti, Angela, Falvo, Francesca, Roppa, Katia, Arbitrio, Mariamena, Guzzi, Pietro Hiram, Agapito, Giuseppe, Pisani, Antonio, Riccio, Eleonora, Concolino, Daniela, Pensabene, Licia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746088/ https://www.ncbi.nlm.nih.gov/pubmed/29296186 http://dx.doi.org/10.18632/oncotarget.22505 |
Ejemplares similares
-
Genetic variants associated with gastrointestinal symptoms in Fabry disease
por: Di Martino, Maria Teresa, et al.
Publicado: (2016) -
Gastrointestinal Symptoms of Patients with Fabry Disease
por: Pensabene, Licia, et al.
Publicado: (2016) -
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2018) -
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
por: Arbitrio, Mariamena, et al.
Publicado: (2018) -
DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
por: Arbitrio, Mariamena, et al.
Publicado: (2016)